|
|
Article: SurModics and NuPathe Partner to Develop Novel Long-Acting Parkinson's Treatment.
- Article from:
- Business Wire
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EDEN PRAIRIE, Minn. & CONSHOHOCKEN, Pa. -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced today that the companies have entered into a license agreement for drug delivery technology. The companies have been collaborating since 2007 on the development of a biodegradable sustained release formulation of an approved dopamine agonist. The result is NuPathe's NP201, the first long-acting treatment available in broadly acceptable dose form that maintains the potential to provide sustained relief from ...
Related newspaper, magazine, and journal articles:
|
|
Article: SurModics acquires remaining portion of InnoRx for $4.1M.
Medical Device Daily;
January 20, 2005 ;
700+ words
...SurModics acquires remaining portion of InnoRx ... Medical Device Daily Managing Editor SurModics (Eden Prairie, Minnesota), a provider ... ophthalmology. Prior to the acquisition, SurModics held an ownership interest in InnoRx ...
|
|